Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats
2019 ◽
Vol 10
(4)
◽
pp. 933-946
◽
2014 ◽
Vol 66
(7)
◽
pp. 975-987
◽
Keyword(s):
2016 ◽
Vol 32
(3)
◽
pp. 329-336
◽
Keyword(s):
Keyword(s):
2015 ◽
Vol 2015
◽
pp. 1-9
◽
2017 ◽
Vol 69
(5)
◽
pp. 995-1000
◽
2014 ◽
Vol 25
(1)
◽
Keyword(s):